Shaban Athuman
/
VPM News
Almost 40% of the county’s 2024 homicides were from instances of IPV.
Spotlight on VPM Original Content
RVA's Got Issues
VPM 60th Anniversary
Virginia News
NPR News
Virginia News
-
Maggie Clemmons is on leave amid review of workplace culture and harassment allegations. -
Retired Army Maj. Gen. Cedric T. Wins' ouster follows pushback on DEI by some conservative alumni.
-
Who’s Dillon, and why does the commonwealth follow his rule?
-
The board initially sought a $43.7M hike over the previous year.
-
Virginia is the only state that requires lawmakers to approve individual payments.
-
The plaque gives context to the sale of enslaved people in the Charlottesville area.
NPR News
-
Two former dancers allege that they lived under a culture of fear and routinely performed despite injuries. Shen Yun has vehemently denied the claims.
-
A few years ago, "A" experienced a psychotic episode. His boss made a decision that saved his life.
-
The Trump administration has launched a $500 million project to develop a universal flu vaccine that won't need yearly updates. But vaccine experts are mystified by its focus on a dated technology.
-
Veterans and others express outrage as the Trump administration ends special protective status for Afghans who had relocated to the U.S.
-
Major League Baseball has lifted the lifetime ban of Pete Rose, "Shoeless" Joe Jackson and 15 other deceased players. The move clears the way for a Hall of Fame vote but doesn't guarantee admission.
Arts & Culture
- Tara Roberts helps scuba divers uncover slave shipwrecks
- New Burying Ground honors enslaved labor at University of Richmond
- Museums, libraries and cultural groups grapple with federal humanities cuts
- ‘Idleness and boredom’: Virginia juvenile justice system strained by staffing shortages
Listen to VPM
- VPM Daily Newscast: Richmond City Council finalizes $3 billion FY26 budget
- Guest conductor Michael Repper leads the Richmond Symphony in Berlioz's Symphonie Fantastique
- VPM Daily Newscast: ‘Catalyst’ UVA Manning Institute for Biotechnology
- Interview: Keep finds the new normal